Clinical Trial Update: Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis [Phase 2, Phase 3]

View source ↗

Summary

Trial update on Xeligekimab for non-radiographic axial spondyloarthritis; Phase 2/3 study assessing efficacy and safety. The study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-radiographic Axial Spondyloarthritis

Drugs mentioned

• Xeligekimab

Snippet

Sponsor: Lingli Dong | Conditions: Nr-axial Spondyloarthritis, Non-Radiographical Axial Spondyloarthritis | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING